Target intelligence / Profile preview

Interleukin-12 receptor (IL-12R)

Target
IL-12R
Molecular classification
Receptor, Cytokine receptor family, Type I cytokine receptor
01

Overview

Interleukin-12 receptor is a heterodimeric type I cytokine receptor composed of two subunits, IL-12Rβ1 and IL-12Rβ2, mainly expressed on T cells and natural killer cells. This receptor binds interleukin-12, a heterodimeric cytokine composed of p35 and p40 subunits, triggering activation of JAK2/TYK2 kinases and STAT4 signaling. IL-12 receptor engagement promotes Th1 differentiation, cytotoxic activity, and interferon-gamma production, playing a critical role in mediating the pro-inflammatory immune response and bridging innate and adaptive immunity. Dysregulation of this pathway is implicated in the pathogenesis of autoimmune and inflammatory diseases, cancer, and infection. Therapeutic agents targeting IL-12 or its shared p40 subunit have shown efficacy in certain inflammatory conditions but may carry risks of immune suppression and infections.

Other names
IL-12RIL-12Rβ1/β2 complexInterleukin 12 receptor beta 1Interleukin 12 receptor beta 2IL12RB1IL12RB2
02

Mechanism of action

Neutralization of IL-12/IL-23 p40 subunit, blocking IL-12 and IL-23 signaling Inhibition of Th1 and Th17 cell differentiation and associated inflammatory responses

03

Biological functions

Signal transductionImmune responseT cell differentiation (Th1 polarization)Induction of interferon-gamma productionCytotoxic activation of natural killer (NK) cells and CD8+ T cellsPromotion of inflammatory cytokine responses
04

Disease associations

CancerInflammationAutoimmune diseaseInfectionPsoriasisInflammatory bowel diseaseAlzheimer's disease
05

Safety considerations

Increased risk of infections (including opportunistic)Impaired anti-tumor immunityImmune suppression leading to reactivation of latent infectionsPossible autoimmune effects due to immune modulation
06

Interacting drugs

Ustekinumab (targets both IL-12 and IL-23 by binding their shared subunit p40)

2 more in the full profile.

07

Biomarkers

IL-12/IL-12Rβ2 expression levels (for immune activation)IFN-gamma productionCXCL10 (IP-10) for anti-angiogenic activityCirculating IL-12/IL-23 p40 levels in some inflammatory diseases

Beyond the preview

Go deeper on Interleukin-12 receptor (IL-12R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-12 receptor (IL-12R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call